Эхинококк IgG

The Echinococcus IgG antibody test (Anti‑Echinococcus IgG) assists in identifying infection with larval stages of Echinococcus granulosus or Echinococcus multilocularis, the parasites that cause echinococcosis. It supports the diagnostic workup when imaging or clinical assessment suggests hydatid disease involving the liver, lungs, kidneys, or other organs. This serologic assay also helps track disease activity over time. Echinococcus‑specific IgG typically becomes detectable 6–8 weeks after infection, reaches peak concentrations by 2–3 months, and can remain elevated for prolonged periods. After treatment, declining IgG levels over the subsequent 2–3 months may indicate therapeutic response. Testing is appropriate for individuals with relevant exposures, including residents of endemic regions and persons with occupational contact with canids.

Echinococcus granulosus and Echinococcus multilocularis are tapeworms that cause echinococcosis in humans, classically manifesting as cystic (unilocular) or alveolar (multilocular) disease, respectively. Canids serve as the definitive hosts, shedding eggs in feces that contaminate soil, water, food, and animal fur. Humans act as intermediate hosts and acquire infection via the fecal–oral route through ingestion of eggs from contaminated environments or contact with infected animals. After ingestion, oncospheres emerge in the small intestine, traverse the mucosa, and disseminate hematogenously. The liver is most frequently involved, with the lungs less commonly affected; the brain, heart, and kidneys are occasional sites. Involved tissues develop parasitic cysts that enlarge slowly over months to years, with single or multiple cysts reaching sizes from several millimeters to 20 cm or more. Disease severity reflects cyst location, number, and size. In cystic echinococcosis, lesions compress adjacent structures, while alveolar disease infiltrates surrounding tissues. Suppuration and cyst rupture can occur, leading to spread of the parasite with formation of daughter cysts and, in some cases, anaphylactic shock. Exposure elicits an immune response with IgM and IgG antibodies. Echinococcus‑specific IgG appears approximately 6–8 weeks after infection, peaks at 2–3 months, and may persist at high levels for extended periods; higher concentrations often parallel greater disease burden. Following successful therapy, IgG concentrations can decrease within 2–3 months. Measurement of IgG antibodies is a central element of laboratory diagnosis of echinococcosis.